Neurocrine Biosciences, Inc [NBIX] stock is trading at $147.58, up 0.56%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The NBIX shares have gain 3.52% over the last week, with a monthly amount glided 9.35%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Piper Sandler upgraded its rating to Overweight on August 29, 2024, and elevated its price target to $159. On April 24, 2024, upgrade upgraded it’s rating to Overweight and revised its price target to $170 on the stock. Deutsche Bank initiated its recommendation with a Buy and recommended $136 as its price target on December 12, 2023. In a note dated August 21, 2023, Mizuho reiterated an Neutral rating on this stock and boosted its target price from $112 to $113.
Neurocrine Biosciences, Inc [NBIX] stock has fluctuated between $110.95 and $157.98 over the past year. Currently, Wall Street analysts expect the stock to reach $155 within the next 12 months. Neurocrine Biosciences, Inc [NASDAQ: NBIX] shares were valued at $147.58 at the most recent close of the market. An investor can expect a potential return of 5.03% based on the average NBIX price forecast.
Analyzing the NBIX fundamentals
Neurocrine Biosciences, Inc [NASDAQ:NBIX] reported sales of 2.24B for the trailing twelve months, which represents a growth of 24.72%. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at 0.26%, Pretax Profit Margin comes in at 0.23%, and Net Profit Margin reading is 0.17%. To continue investigating profitability, this company’s Return on Assets is posted at 0.11, Equity is 0.16 and Total Capital is 0.19. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.09.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 146.15 points at the first support level, and at 144.71 for the second support level. However, for the 1st resistance point, the stock is sitting at 148.87, and for the 2nd resistance point, it is at 150.15.
Ratios To Look Out For
For context, Neurocrine Biosciences, Inc’s Current Ratio is 4.37. As well, the Quick Ratio is 4.26, while the Cash Ratio is 0.81. Considering the valuation of this stock, the price to sales ratio is 6.66, the price to book ratio is 5.49 and price to earnings (TTM) ratio is 39.54.
Transactions by insiders
Recent insider trading involved Gano Kyle, Chief Executive Officer, that happened on Jan 15 ’25 when 65000.0 shares were sold. Officer, KYLE W GANO completed a deal on Jan 15 ’25 to buy 65000.0 shares. Meanwhile, Chief Regulatory Officer Delaet Ingrid sold 272.0 shares on Dec 31 ’24.
